受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
||||
化学式 | C23H27N3O5S2 |
||||||
分子量 | 489.61 | CAS No. | 300802-28-2 | ||||
Solubility (25°C)* | 体外 | DMSO | 97 mg/mL (198.11 mM) | ||||
Water | Insoluble | ||||||
Ethanol | Insoluble | ||||||
体内 (毎回新しく調製した物を用意してください) |
|
||||||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | CA3 (CIL56) has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. CA3(CIL56) induces ferroptosis and iron-dependent reactive oxygen species (ROS). |
---|---|
in vitro | CA3 strongly inhibits esophageal adenocarcinoma cell growth in vitro. CA3 can effectively suppress tumor cell proliferation, induce apoptosis, reduce tumor sphere formation, and the population of ALDH1+ cells. CA3 specially inhibits Tead/YAP1 transcriptional activity but shows no inhibitory activity on other transcriptional factors-Super-TOP/Wnt, CBF1/Notch, and AP-1 after cotransfection of their respective individual promoter luciferases in 293T cells. CA3 preferentially inhibits CSC properties enriched in radiation-resistant esophageal adenocarcinoma cells[1]. |
in vivo | CA3 exerts strong antitumor activity in xenograft model with no apparent toxicity[1]. |
細胞アッセイ | 細胞株 | SKGT-4 and JHESO cells |
---|---|---|
濃度 | 0.5 and 1 μmol/L | |
反応時間 | 48 hours | |
実験の流れ | SKGT-4 and JHESO cells are seeded onto 6-well plates (1 × 105/well) in DMEM and cultured for 24 hours to allow for cell attachment. The cells are then treated with 0.1% DMSO (control) or CA3 at different doses as indicated for 48 hours. Next, the cells are harvested, fixed with methanol, washed, treated with RNase A, and stained for DNA with propidium iodide, and their DNA histograms and cell-cycle phase distributions are analyzed using flow cytometry. |
|
動物実験 | 動物モデル | A JHESO xenograft model of esophageal adenocarcinoma |
投薬量 | 1 mg/kg/mouse | |
投与方法 | i.p. |
Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity [ Cell Rep, 2024, 43(4):114003] | PubMed: 38527062 |
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma [ Nat Commun, 2023, 14(1):6699] | PubMed: 37872167 |
Musculoskeletal defects associated with myosin heavy chain-embryonic loss of function are mediated by the YAP signaling pathway [ EMBO Mol Med, 2023, e17187.] | PubMed: 37492882 |
Extracellular Vesicles Derived circSH3PXD2A Inhibits Chemoresistance of Small Cell Lung Cancer by miR-375-3p/YAP1 [ Int J Nanomedicine, 2023, 18:2989-3006] | PubMed: 37304971 |
Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms [ Cancers (Basel), 2023, 15(20)4960] | PubMed: 37894327 |
Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms [ Cancers (Basel), 2023, 10.3390/cancers15204960] | PubMed: 37894327 |
Different stimuli induce endothelial dysfunction and promote atherosclerosis through the Piezo1/YAP signaling axis [ Arch Biochem Biophys, 2023, 10.1016/j.abb.2023.109755] | PubMed: 37714252 |
RP11-40C6.2 Inactivates Hippo Signaling by Attenuating YAP1 Ubiquitylation in Hepatitis B Virus-associated Hepatocellular Carcinoma [ J Clin Transl Hepatol, 2023, 11(2):323-333] | PubMed: 36643034 |
The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in HCT116 colon cancer cells [ bioRxiv, 2023, 10.1101/2023.03.17.533075] | PubMed: None |
YAP signaling regulates the cellular uptake and therapeutic effect of nanoparticles [ bioRxiv, 2023, 10.1101/2023.03.10.532035] | PubMed: None |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。